ACRSHealthcareSmall-Cap

Aclaris Therapeutics, Inc. Insider Trading Activity

Every SEC Form 4 insider transaction reported for Aclaris Therapeutics, Inc. (ACRS), sourced directly from SEC EDGAR and updated as new filings are accepted.

Last updated:

Quick Answer

Are ACRS insiders buying or selling?

Aclaris Therapeutics, Inc. insiders reported 19 open-market buys ($11.7M) and 43 sells ($27.4M) across 62 Form 4 filings — a net selling position of $15.7M.

Source: SEC EDGAR Form 4

Key Statistics (as of Apr 27, 2026)

Total Form 4 filings
62
SEC EDGAR
Insider filers
14
Insider buys (19)
$11.7M
Insider sells (43)
$27.4M

Insider sentiment

Net selling

Net insider flow of $15.7M in net selling.

Recent ACRS insider transactions

DateInsiderRoleTypeSharesPriceValue
Apr 27, 2026Braden Michael Leonard10% OwnerSale300.0K$4.53$1.4M
Nov 20, 2024Anand MehraDirectorPurchase666.7K$2.25$1.5M
Aug 5, 2024Braden Michael Leonard10% OwnerPurchase373.6K$1.27$472.8K
Jul 31, 2024Braden Michael Leonard10% OwnerPurchase273.7K$1.31$359.0K
Jul 22, 2024Braden Michael Leonard10% OwnerPurchase154.7K$1.30$201.8K
Jul 5, 2024Braden Michael Leonard10% OwnerPurchase352.4K$1.15$405.9K
Jul 1, 2024Braden Michael Leonard10% OwnerPurchase1.5M$1.13$1.7M
Jun 18, 2024Braden Michael Leonard10% OwnerPurchase545.0K$1.15$628.2K
Jun 13, 2024Braden Michael Leonard10% OwnerPurchase1.6M$1.11$1.8M
Mar 5, 2024Andrew Kenneth William PowellDirectorPurchase14.5K$1.24$18.0K
Oct 25, 2023Joseph MonahanChief Scientific OfficerSale6.0K$5.08$30.5K
Sep 7, 2023Kevin BalthaserChief Financial OfficerPurchase9.5K$7.90$75.0K
Aug 28, 2023James LoeropChief Business OfficerPurchase14.7K$6.80$100.0K
Aug 22, 2023Joseph MonahanChief Scientific OfficerSale6.0K$7.32$43.9K
Jun 22, 2023Joseph MonahanChief Scientific OfficerSale6.0K$10.28$61.7K
Mar 17, 2023Douglas J. ManionPres and CEOPurchase6.3K$7.86$49.5K
Mar 9, 2023Douglas J. ManionPres and CEOPurchase6.5K$7.74$50.3K
Mar 4, 2023Neal WalkerDirectorSale59.2K$12.50$740.7K
Mar 4, 2023Joseph MonahanChief Scientific OfficerSale30.8K$12.51$385.6K
Feb 17, 2023Joseph MonahanChief Scientific OfficerSale5.0K$13.06$65.3K
Feb 10, 2023James LoeropChief Business OfficerSale4.3K$13.89$59.3K
Feb 3, 2023Neal WalkerDirectorSale30.0K$16.66$499.9K
Jan 4, 2023Neal WalkerDirectorSale40.0K$15.11$604.6K
Dec 16, 2022Joseph MonahanChief Scientific OfficerSale5.0K$15.88$79.4K
Nov 14, 2022Andrew N SchiffDirectorSale53.9K$17.05$919.6K

Showing the 25 most recent of 62 Form 4 filings for Aclaris Therapeutics, Inc..

Most active ACRS insiders

  • Joseph Monahan11 filings
  • Braden Michael Leonard8 filings
  • Neal Walker8 filings
  • Andrew N Schiff6 filings
  • Kamil Ali-Jackson6 filings

Ask anything about ACRS insider activity

Use Trabud's AI agent to query Aclaris Therapeutics, Inc.'s Form 4 history in plain English — "Show me ACRS CEO purchases this year" or compare it against any other ticker.

Open the AI agent

ACRS insider trading FAQ

Are Aclaris Therapeutics, Inc. insiders buying or selling?

Across 62 SEC Form 4 filings, Aclaris Therapeutics, Inc. (ACRS) insiders reported 19 open-market purchases totaling $11.7M and 43 sales totaling $27.4M. That is a net selling position of $15.7M.

How many insiders trade ACRS stock?

14 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Aclaris Therapeutics, Inc.. The most recent filing was accepted on Apr 27, 2026.

Where does Trabud get ACRS insider trading data?

All ACRS insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.

Looking for another company? Browse all tracked companies.

Related Content